NL2014935B1 - T cell receptor like antibodies having fine specificity. - Google Patents

T cell receptor like antibodies having fine specificity. Download PDF

Info

Publication number
NL2014935B1
NL2014935B1 NL2014935A NL2014935A NL2014935B1 NL 2014935 B1 NL2014935 B1 NL 2014935B1 NL 2014935 A NL2014935 A NL 2014935A NL 2014935 A NL2014935 A NL 2014935A NL 2014935 B1 NL2014935 B1 NL 2014935B1
Authority
NL
Netherlands
Prior art keywords
antibody
hla
binding
peptide
amino acid
Prior art date
Application number
NL2014935A
Other languages
English (en)
Dutch (nl)
Other versions
NL2014935A (en
Inventor
Peled Kamar Mira
Denkberg Galit
Reiter Yoram
Beer Ilan
Sinik Keren
Teboul Yael (Elbaz)
Shperber Yael (Sery)
Erel Segal Reut
Original Assignee
Applied Immune Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NL2014935A priority Critical patent/NL2014935B1/en
Application filed by Applied Immune Tech Ltd filed Critical Applied Immune Tech Ltd
Priority to IL256178A priority patent/IL256178B2/en
Priority to CA3220475A priority patent/CA3220475A1/en
Priority to MX2017015928A priority patent/MX2017015928A/es
Priority to KR1020177037826A priority patent/KR20180011275A/ko
Priority to CN202210030010.4A priority patent/CN114437217B/zh
Priority to AU2016276555A priority patent/AU2016276555B2/en
Priority to KR1020187000504A priority patent/KR20180012851A/ko
Priority to PCT/IL2016/050600 priority patent/WO2016199141A2/en
Priority to CN202210349590.3A priority patent/CN114605547B/zh
Priority to ES16739266T priority patent/ES2922236T3/es
Priority to PCT/IL2016/050599 priority patent/WO2016199140A1/en
Priority to CN201680039192.4A priority patent/CN107847569A/zh
Priority to CN201680040163.XA priority patent/CN108025045B/zh
Priority to CA2987889A priority patent/CA2987889A1/en
Priority to EP24193198.9A priority patent/EP4488293A3/en
Priority to EP22154188.1A priority patent/EP4039270A1/en
Priority to EP16739266.1A priority patent/EP3302538B1/en
Priority to US15/579,616 priority patent/US11001642B2/en
Priority to JP2017563328A priority patent/JP7013243B2/ja
Priority to SG10202007398PA priority patent/SG10202007398PA/en
Priority to MX2017015801A priority patent/MX394431B/es
Priority to JP2017563331A priority patent/JP6912392B2/ja
Priority to CA2988270A priority patent/CA2988270A1/en
Priority to EP16734763.2A priority patent/EP3302537A1/en
Priority to AU2016276556A priority patent/AU2016276556C1/en
Publication of NL2014935A publication Critical patent/NL2014935A/en
Application granted granted Critical
Publication of NL2014935B1 publication Critical patent/NL2014935B1/en
Priority to MX2022009493A priority patent/MX2022009493A/es
Priority to IL256177A priority patent/IL256177A/en
Priority to US17/317,824 priority patent/US12252547B2/en
Priority to JP2021113633A priority patent/JP7147018B2/ja
Priority to JP2022150286A priority patent/JP7376655B2/ja
Priority to AU2022268398A priority patent/AU2022268398A1/en
Priority to IL304821A priority patent/IL304821A/en
Priority to JP2023183842A priority patent/JP2024016092A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NL2014935A 2015-06-08 2015-06-08 T cell receptor like antibodies having fine specificity. NL2014935B1 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
NL2014935A NL2014935B1 (en) 2015-06-08 2015-06-08 T cell receptor like antibodies having fine specificity.
CA3220475A CA3220475A1 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
MX2017015928A MX2017015928A (es) 2015-06-08 2016-06-08 Anticuerpos similares al receptor de celulas t que tienen una especificidad fina.
KR1020177037826A KR20180011275A (ko) 2015-06-08 2016-06-08 우수한 특이성을 가진 t 세포 수용체 유사 항체
CN202210030010.4A CN114437217B (zh) 2015-06-08 2016-06-08 具有类tcr抗体结合域的亲和性实体及其用途
AU2016276555A AU2016276555B2 (en) 2015-06-08 2016-06-08 T cell receptor like antibodies having fine specificity
KR1020187000504A KR20180012851A (ko) 2015-06-08 2016-06-08 고 친화성 및 고 특이성을 가진 tcr-유사 항체 결합 도메인을 포함하는 친화성 엔티티 및 이의 용도
PCT/IL2016/050600 WO2016199141A2 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
CN202210349590.3A CN114605547B (zh) 2015-06-08 2016-06-08 具有类tcr抗体结合域的亲和性实体及其用途
ES16739266T ES2922236T3 (es) 2015-06-08 2016-06-08 Entidades de afinidad que comprenden un dominio de unión a anticuerpo similar a TCR con gran afinidad y buena especificidad y usos de las mismas
PCT/IL2016/050599 WO2016199140A1 (en) 2015-06-08 2016-06-08 T cell receptor like antibodies having fine specificity
CN201680039192.4A CN107847569A (zh) 2015-06-08 2016-06-08 具有优良特异性的类t细胞受体抗体
CN201680040163.XA CN108025045B (zh) 2015-06-08 2016-06-08 具有高亲和性和优良特异性的类tcr抗体结合域的亲和性实体及其用途
CA2987889A CA2987889A1 (en) 2015-06-08 2016-06-08 T cell receptor like antibodies having fine specificity
EP24193198.9A EP4488293A3 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
EP22154188.1A EP4039270A1 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
IL256178A IL256178B2 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
EP16739266.1A EP3302538B1 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
US15/579,616 US11001642B2 (en) 2015-06-08 2016-06-08 Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same
SG10202007398PA SG10202007398PA (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
MX2017015801A MX394431B (es) 2015-06-08 2016-06-08 Entidades de afinidad que comprenden un dominio de unión de anticuerpo similar al tcr con alta afinidad y especificidad fina y usos de las mismas.
JP2017563331A JP6912392B2 (ja) 2015-06-08 2016-06-08 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用
CA2988270A CA2988270A1 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
EP16734763.2A EP3302537A1 (en) 2015-06-08 2016-06-08 T cell receptor like antibodies having fine specificity
AU2016276556A AU2016276556C1 (en) 2015-06-08 2016-06-08 Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same
JP2017563328A JP7013243B2 (ja) 2015-06-08 2016-06-08 微細特異性を有する親和性結合体
MX2022009493A MX2022009493A (es) 2015-06-08 2017-12-06 Entidades de afinidad que comprenden un dominio de union de anticuerpo similar al tcr con alta afinidad y especificidad fina y usos de las mismas.
IL256177A IL256177A (en) 2015-06-08 2017-12-07 T cell receptor like antibodies having fine specificity
US17/317,824 US12252547B2 (en) 2015-06-08 2021-05-11 Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same
JP2021113633A JP7147018B2 (ja) 2015-06-08 2021-07-08 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用
JP2022150286A JP7376655B2 (ja) 2015-06-08 2022-09-21 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用
AU2022268398A AU2022268398A1 (en) 2015-06-08 2022-11-11 Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same
IL304821A IL304821A (en) 2015-06-08 2023-07-30 Entities with high affinity and fine binding specificity containing binding regions of T cell receptor-like antibodies and their uses
JP2023183842A JP2024016092A (ja) 2015-06-08 2023-10-26 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2014935A NL2014935B1 (en) 2015-06-08 2015-06-08 T cell receptor like antibodies having fine specificity.

Publications (2)

Publication Number Publication Date
NL2014935A NL2014935A (en) 2016-12-12
NL2014935B1 true NL2014935B1 (en) 2017-02-03

Family

ID=54325627

Family Applications (1)

Application Number Title Priority Date Filing Date
NL2014935A NL2014935B1 (en) 2015-06-08 2015-06-08 T cell receptor like antibodies having fine specificity.

Country Status (13)

Country Link
US (2) US11001642B2 (https=)
EP (4) EP4488293A3 (https=)
JP (5) JP7013243B2 (https=)
KR (2) KR20180011275A (https=)
CN (4) CN114605547B (https=)
AU (3) AU2016276555B2 (https=)
CA (3) CA3220475A1 (https=)
ES (1) ES2922236T3 (https=)
IL (3) IL256178B2 (https=)
MX (3) MX394431B (https=)
NL (1) NL2014935B1 (https=)
SG (1) SG10202007398PA (https=)
WO (2) WO2016199141A2 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
KR102643923B1 (ko) 2014-12-23 2024-03-05 이매틱스 바이오테크놀로지스 게엠베하 간세포 암종(hcc) 및 기타 암들에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
WO2017060201A1 (en) * 2015-10-09 2017-04-13 Immatics Biotechnologies Gmbh Anti-wt1/hla-specific antibodies
EP3842450A1 (en) 2015-10-23 2021-06-30 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
EP3573997A4 (en) * 2017-01-24 2020-12-09 Abexxa Biologics, Inc. METHODS AND COMPOSITIONS INTENDED TO TARGE A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN IN THE TREATMENT OF CANCER
WO2018200585A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Cells expressing chimeric antigen receptors and secondary effectors and uses thereof
US11807662B2 (en) 2017-05-16 2023-11-07 The Johns Hopkins University MANAbodies and methods of using
CN110709424B (zh) * 2017-05-31 2024-01-05 科济生物医药（上海）有限公司 细胞免疫治疗的组合物和方法
US11497768B2 (en) * 2017-06-05 2022-11-15 Mie University Antigen-binding protein that recognizes MAGE-A4-derived peptide
AU2017418590A1 (en) 2017-06-14 2020-01-16 Adicet Therapeutics, Inc. Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
SG11202005632SA (en) 2017-12-21 2020-07-29 Hoffmann La Roche Antibodies binding to hla-a2/wt1
WO2019165307A1 (en) * 2018-02-23 2019-08-29 Abexxa Biologics, Inc. Combination cancer therapy with anti-cancer agents and antibodies targeting a complex comprising non-classical hla-i and neoantigen
GB201803750D0 (en) 2018-03-08 2018-04-25 Immunocore Ltd Method
WO2019192972A1 (en) * 2018-04-04 2019-10-10 F. Hoffmann-La Roche Ag Diagnostic assays to detect tumor antigens in cancer patients
AU2019283639A1 (en) * 2018-06-04 2021-01-07 Apo-T B.V. Methods and means for attracting immune effector cells to tumor cells
EP3823988A1 (en) * 2018-07-19 2021-05-26 Eli Lilly and Company Bispecific antibodies targeting immune checkpoints
JP7156653B2 (ja) * 2018-08-30 2022-10-19 イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ 固形腫瘍を治療するためのキメラ抗原受容体細胞
CN113272016A (zh) * 2018-10-01 2021-08-17 阿迪塞特生物股份有限公司 关于治疗实体肿瘤的工程化和非工程化γδ-T细胞的组合物和方法
AU2019354391A1 (en) 2018-10-01 2021-05-06 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non- engineered γδ-Τ cells for treatment of hematological tumors
EP3917542A4 (en) * 2019-01-29 2023-03-08 Gritstone bio, Inc. MULTISPECIFIC BINDING PROTEINS
JP7748284B2 (ja) 2019-03-04 2025-10-02 ユニバーシティー ヘルス ネットワーク Ｔ細胞受容体及びその使用方法
MX2021010541A (es) 2019-03-04 2021-12-15 Univ Health Network Receptores de linfocitos t y metodos de uso de estos.
CN113795586B (zh) * 2019-03-25 2026-03-27 大学健康网络 T细胞受体及其使用方法
GB201904328D0 (en) * 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
KR20220030933A (ko) 2019-05-08 2022-03-11 메디진 이뮤노테라피스 게엠바하 조작된 t 세포
BR112021025548A2 (pt) * 2019-06-18 2022-05-17 Regeneron Pharma Receptores de células t mage-a4 e métodos de uso dos mesmos
MX2022000896A (es) * 2019-07-24 2022-02-14 Regeneron Pharma Receptores de antigenos quimericos con especificidad por mage-a4 y usos de los mismos.
US12480958B2 (en) 2019-08-13 2025-11-25 Immatics Biotechnologies Gmbh Method for the characterization of peptide:MHC binding polypeptides
CN112442119B (zh) * 2019-09-05 2023-02-24 香雪生命科学技术（广东）有限公司 一种识别ssx2的高亲和力t细胞受体
CN110563804A (zh) * 2019-09-19 2019-12-13 河南省农业科学院 基于天然免疫库筛选识别氧氟沙星单链抗体的多肽序列及应用
NL2024375B1 (en) * 2019-12-04 2021-08-31 Apo T B V Methods and means for attracting immune effector cells to tumor cells.
CR20220256A (es) 2019-12-18 2022-08-31 Hoffmann La Roche Anticuerpos que se unen a hla-a2/mage-a4
AU2021266706A1 (en) * 2020-05-05 2022-12-15 Regeneron Pharmaceuticals, Inc. Car comprising CD28 zeta and CD3 zeta
US12312412B2 (en) 2020-05-19 2025-05-27 Amgen Inc. MAGEB2 binding constructs
EP4164696A1 (en) * 2020-06-11 2023-04-19 Innovative Cellular Therapeutics Holdings, Ltd. Cell/gene therapies targeting mage-a4 peptide
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
WO2022101120A1 (en) * 2020-11-10 2022-05-19 F. Hoffmann-La Roche Ag Prevention or mitigation of t-cell engaging agent-related adverse effects
EP4304725A1 (en) * 2021-03-09 2024-01-17 CDR-Life AG Rabbit-derived antigen binding protein nucleic acid libraries
US11912771B2 (en) 2021-03-09 2024-02-27 Cdr-Life Ag MAGE-A4 peptide-MHC antigen binding proteins
CA3217914A1 (en) * 2021-05-04 2022-11-10 Kevin BRAY Chimeric antigen receptors with mage-a4 specificity and uses thereof
JP2024546589A (ja) * 2021-12-14 2024-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｌａ－ａ２／ｍａｇｅ－ａ４×ｃｄ３二重特異性抗体及び４－１ｂｂ（ｃｄ１３７）アゴニストを使用したがんの治療
KR20250067130A (ko) 2022-09-14 2025-05-14 씨디알-라이프 아게 Mage-a4 펩티드 이중 t 세포 연결체
WO2025064029A1 (en) * 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibody molecules binding to a peptide-mhc interface
GB202315181D0 (en) * 2023-10-03 2023-11-15 Immunocore Ltd Peptide-HLA binding molecules

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US8258260B2 (en) 1970-02-11 2012-09-04 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
WO1997015597A1 (en) 1995-10-25 1997-05-01 Centocor B.V. HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE
WO2000020445A2 (en) 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US7521202B2 (en) 1999-12-17 2009-04-21 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of soluble MHC antigens and uses thereof
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20070099182A1 (en) 2000-10-10 2007-05-03 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20090062512A1 (en) 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
DE10225144A1 (de) 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
DE10313819A1 (de) 2003-03-24 2004-10-07 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US7488793B2 (en) 2003-09-22 2009-02-10 Ludwig Institute For Cancer Research Isolated peptide which binds to HLA-Cw*07 and uses thereof
DK1765860T3 (da) 2004-05-19 2009-03-09 Immunocore Ltd Ny-ESO-T.cellereceptor med höj affinitet
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
DK1758935T3 (da) 2004-05-26 2009-08-10 Immunocore Ltd Telomerase-T-cellereceptorer med höj affinitet
GB0411773D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
PL1642905T3 (pl) 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
NZ561338A (en) 2005-04-01 2010-04-30 Immunocore Ltd High affinity HIV T cell receptors
ES2367643T3 (es) 2005-04-26 2011-11-07 Immatics Biotechnologies Gmbh Identificador de un epítopo de linfocitos t presentado por el antígeno hla-a2 y derivado de la proteína del receptor de laminina inmadura del antígeno oncofetal y usos de este.
GB0524477D0 (en) 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
ES2341802T3 (es) 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
US20090028888A1 (en) * 2005-11-14 2009-01-29 Alain Bergeron Cancer Antigen Mage-A9 and Uses Thereof
WO2007143104A2 (en) * 2006-06-01 2007-12-13 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
DE102007001370A1 (de) * 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
CA2682093A1 (en) * 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
EA018457B1 (ru) 2007-07-27 2013-08-30 Имматикс Байотекнолоджиз Гмбх Композиция опухолеассоциированных пептидов и относящаяся к ним противораковая вакцина
BRPI0813621A2 (pt) 2007-07-27 2017-05-09 Immatics Biotechnologies Gmbh imunoterapia contra tumores neuronais e cerebrais
PL2565204T3 (pl) 2007-07-27 2016-03-31 Immatics Biotechnologies Gmbh Nowe immunogenne epitopy do immunoterapii
US20110105724A1 (en) 2007-08-16 2011-05-05 Stephanie Jane Clegg Novel compounds
WO2009090651A2 (en) 2008-01-15 2009-07-23 Technion Research And Development Foundation Ltd. Major histocompatibility complex hla-b2705 ligands useful for therapy and diagnosis
PT2113253E (pt) 2008-04-30 2010-06-15 Immatics Biotechnologies Gmbh Formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) para vacinas
SI2119726T2 (en) 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
WO2010106535A1 (en) 2009-03-15 2010-09-23 Technion Research And Development Foundation Ltd. Soluble hla complexes for use in disease diagnosis
ES2625985T3 (es) 2009-03-25 2017-07-21 Altor Bioscience Corporation Receptores de linfocitos T específicos de la vpr del VIH
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
EP2501722A4 (en) * 2009-11-19 2013-05-01 Univ Singapore METHOD FOR PRODUCING T-CELL-RECEPTOR-SIMILAR MONOCLONAL ANTIBODIES AND APPLICATIONS THEREOF
US9023802B2 (en) 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201019331D0 (en) 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
SG185107A1 (en) * 2010-04-30 2012-12-28 Alexion Pharma Inc Antibodies having reduced immunogenicity in a human
US9821073B2 (en) 2010-12-27 2017-11-21 Apo-T B.V. Polypeptide that binds aberrant cells and induces apoptosis
SG193023A1 (en) 2011-02-11 2013-10-30 Sloan Kettering Inst Cancer Hla-restricted, peptide-specific antigen binding proteins
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
KR20140033029A (ko) 2011-04-01 2014-03-17 메모리얼 슬로안-케터링 캔서 센터 에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
AU2013208364B2 (en) 2012-01-13 2017-10-26 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
JP6553069B2 (ja) 2013-11-07 2019-07-31 メモリアル スローン ケタリング キャンサー センター 抗ｗｔ１／ｈｌａ二重特異性抗体
EP3066131A1 (en) 2013-11-07 2016-09-14 Memorial Sloan-Kettering Cancer Center Fc-enhanced anti-wt1/hla antibody
AU2016243026B2 (en) 2015-04-03 2022-03-31 Eureka Therapeutics, Inc. Constructs targeting AFP peptide/MHC complexes and uses thereof
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
US20180179283A1 (en) 2015-06-08 2018-06-28 Adicet Bio Inc. T cell receptor like antibodies having fine specificity
AU2017418590A1 (en) 2017-06-14 2020-01-16 Adicet Therapeutics, Inc. Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof

Also Published As

Publication number Publication date
ES2922236T3 (es) 2022-09-12
CN108025045B (zh) 2022-04-26
JP2018526970A (ja) 2018-09-20
EP3302537A1 (en) 2018-04-11
WO2016199141A2 (en) 2016-12-15
US20210388111A1 (en) 2021-12-16
AU2016276555A1 (en) 2018-01-18
JP2024016092A (ja) 2024-02-06
CN114605547A (zh) 2022-06-10
EP4039270A9 (en) 2023-03-22
US11001642B2 (en) 2021-05-11
KR20180012851A (ko) 2018-02-06
AU2016276556B2 (en) 2022-08-11
AU2016276556C1 (en) 2023-01-19
JP7013243B2 (ja) 2022-01-31
CA3220475A1 (en) 2016-12-15
MX2022009493A (es) 2022-12-13
EP4039270A1 (en) 2022-08-10
CN108025045A (zh) 2018-05-11
WO2016199141A3 (en) 2017-01-19
EP4488293A2 (en) 2025-01-08
SG10202007398PA (en) 2020-09-29
MX394431B (es) 2025-03-24
JP2022188107A (ja) 2022-12-20
WO2016199140A8 (en) 2016-12-29
MX2017015801A (es) 2018-08-01
CN114605547B (zh) 2025-02-25
CN114437217B (zh) 2025-03-14
NL2014935A (en) 2016-12-12
KR20180011275A (ko) 2018-01-31
WO2016199141A8 (en) 2017-11-16
JP7147018B2 (ja) 2022-10-04
EP3302538A2 (en) 2018-04-11
JP2018527884A (ja) 2018-09-27
AU2016276556A1 (en) 2018-01-18
EP4488293A3 (en) 2025-03-26
JP6912392B2 (ja) 2021-08-04
AU2016276555B2 (en) 2022-07-21
EP3302538B1 (en) 2022-02-09
JP2021176861A (ja) 2021-11-11
JP7376655B2 (ja) 2023-11-08
IL256177A (en) 2018-02-28
IL256178B1 (en) 2023-09-01
CA2987889A1 (en) 2016-12-15
AU2022268398A1 (en) 2022-12-15
CN114437217A (zh) 2022-05-06
MX2017015928A (es) 2018-06-22
CN107847569A (zh) 2018-03-27
IL256178A (en) 2018-02-28
US20180171024A1 (en) 2018-06-21
IL256178B2 (en) 2024-01-01
WO2016199140A1 (en) 2016-12-15
CA2988270A1 (en) 2016-12-15
IL304821A (en) 2023-09-01
US12252547B2 (en) 2025-03-18

Similar Documents

Publication Publication Date Title
NL2014935B1 (en) T cell receptor like antibodies having fine specificity.
US20180179283A1 (en) T cell receptor like antibodies having fine specificity
CN106632677B (zh) 对hla-a2呈递的wt1肽特异的t细胞受体样抗体
JP7282760B2 (ja) バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
Dahan et al. T-cell-receptor-like antibodies–generation, function and applications
US20100158927A1 (en) Antibodies, methods and kits for diagnosing and treating melanoma
HK1248255A1 (zh) 靶向ny-eso-1肽/mhc复合物的构建体及其用途
HK40069173A (en) Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
WO2024178334A1 (en) Improved phox2b pc-car generation based on structure and saturation mutagenesis